Flunix

Quick links to important sections

Flunix

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flunix

Property Description
Active ingredient Flunixin meglumine
Form Injectable solution, oral paste, granules
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Alleviation of pain, fever, and inflammation
Origin Synthetic, Fenamates derivative

What is Flunix and Its Pharmacological Identity?

Flunix is a commercial name for a compound whose active substance is Flunixin meglumine, which is categorized as a synthetic small molecule primarily designated for use in veterinary medicine. This substance is formally classified as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID) and functions as a powerful Non-narcotic Analgesic. Chemically, Flunixin meglumine is a derivative belonging to the Fenamates class of NSAIDs, distinguishing it from other common anti-inflammatory drugs like propionics. It is clinically recognized for its effectiveness as a fast-acting analgesic in acute settings.


Composition and Available Physical Forms

The active component, Flunixin meglumine, is a single-ingredient product supplied in forms that allow for both parenteral and enteral administration. Preparations include a sterile injectable solution—a format often favored for its rapid onset of action—an oral paste, and granules designed for incorporation into feed. For the injectable preparation, the Flunixin meglumine salt is typically suspended in an aqueous solution base. The availability of these distinct forms allows for flexibility in the route of administration, which is a differentiating factor when managing various animal patient groups, such as administering the paste form to a horse experiencing colic discomfort.


General Purpose: What Core Symptoms Does Flunixin Meglumine Address?

The essential general purpose of Flunixin meglumine is to provide rapid and comprehensive symptomatic relief by interrupting key inflammatory processes. The compound operates as a potent Cyclo-oxygenase (COX) inhibitor, fundamentally blocking the biosynthesis of prostaglandins, which are the biological mediators responsible for pain, inflammation, and high body temperature. This action achieves simultaneous analgesic (pain-alleviating), anti-inflammatory (swelling-reducing), and anti-pyretic (fever-controlling) effects. Furthermore, the drug is recognized for its unique capability as an anti-endotoxic agent, which is crucial in mitigating the severe systemic effects associated with bacterial toxins released during specific acute infections, a feature that distinguishes it from many general NSAIDs.

Regulatory References

  1. FDA: Flunixin Label

What side effects are possible with Flunix?

Possible Side Effects and Safety Information

Flunix (Flunixin Meglumine) is a nonsteroidal anti-inflammatory drug (NSAID) and is associated with a specific safety profile derived from its class and route of administration.

Adverse Reactions

The most commonly reported adverse events primarily involve the gastrointestinal tract, including the risk of ulceration and inflammation of the stomach and large colon, which may be associated with prolonged use. Other documented reactions include kidney damage (renal toxicity) and local tissue irritation at the injection site.

Rare, but serious, adverse reactions have been reported in regulatory documents, including:

  • Anaphylactic-like reactions, some of which have been fatal, typically following intravenous use.
  • Fatal or nonfatal infections (e.g., Clostridial myositis) associated with intramuscular injection in some species.
  • Severe, transient neurological signs, such as ataxia and seizures, following inadvertent intra-arterial injection.

Safety Restrictions and Monitoring

As an NSAID, Flunix should be used with particular caution in patients who are dehydrated, receiving concomitant diuretic therapy, or who have existing renal, cardiovascular, or hepatic impairment. These conditions increase the risk for serious side effects.

Use is contraindicated in animals known to have a hypersensitivity to the drug, or those with existing gastrointestinal ulceration or bleeding disorders. Concomitant use with other NSAIDs or corticosteroids should be avoided due to an increased potential for gastrointestinal toxicity. Certain routes of administration are strongly cautioned against or forbidden (e.g., intra-arterial injection), reflecting route-specific safety risks.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Documented Overdose Presentations

Overdosage of Flunixin meglumine is primarily associated with gastrointestinal toxicity, which constitutes the main documented manifestation in regulatory sources. Clinically, this can involve gastrointestinal irritation, ulceration, and the potential for related complications such as bleeding. Overexposure also carries a risk for renal damage (kidney damage), particularly when administered to animals that are already dehydrated or hypovolaemic.

Severe Outcomes and Emergency Response

The most severe, life-threatening outcomes officially documented include anaphylactic shock and collapse. In rare cases, administration of the injectable solution can trigger life-threatening shock reactions due to the excipient propylene glycol. If such symptoms appear during intravenous use, the injection must be immediately stopped and emergency care initiated. The official labeling specifies that emergency veterinary care must be sought immediately upon suspicion of overdosage or the manifestation of acute toxic signs.

Management and Considerations

Management of overdosage is defined as symptomatic and supportive treatment, as regulatory documents do not specify a known antidote. Overdose risk notes specify that aged animals and those less than six weeks of age may involve additional risk and require careful clinical management to mitigate potential severity.

Therapeutic Uses of Flunix

What Flunix Treats: Main Uses and Benefits

Flunixin meglumine is commonly used in clinical settings that involve acute or unstable symptom patterns, and is applied in addressing symptom clusters related to physical discomfort, fever, and inflammation. Its use is aligned with recognized therapeutic domains in veterinary medicine. It is relevant in conditions characterized by periods of heightened symptoms, such as equine colic (severe abdominal pain), where it provides support that helps ease the overall symptom burden.

The medication is relevant in clinical settings involving heightened systemic burden, such as conditions where symptoms are associated with severe systemic inflammatory response, or in the supportive management of endotoxemia and infectious diseases. It is employed across domains where additional symptomatic support is needed for conditions like Bovine Respiratory Disease (BRD) in cattle, and is used for managing the fever and inflammation associated with acute bovine mastitis and Mastitis-Metritis-Agalactia (MMA) syndrome in sows.

“It is applied during phases of increased distress or discomfort.”

Flunix may assist with symptom clusters that appear suddenly or fluctuate, and generally offers a supportive relief that contributes to easing the overall symptom load related to inflammation and maintaining a sense of stability.


Quick Fact: Relief for Acute Pain The medicine is commonly used to help manage sudden discomfort associated with acute episodes, supporting the patient during difficult symptomatic periods.

Eligibility and Restrictions for Use

Eligibility for Flunix (Flunixin Meglumine)

Official regulatory documents define strict criteria for the use of Flunix, a non-steroidal anti-inflammatory drug (NSAID) approved for horses, cattle, and swine. Use outside these species is not established.

Category Official Regulatory Status
Populations for whom use is allowed Horses, specific classes of cattle (beef, non-dry dairy), and swine, as defined by the label [1.4, 2.4, 3.5].
Populations for whom use is contraindicated Animals with hypersensitivity to flunixin, pre-existing cardiac, hepatic, or renal disease, or risk of gastrointestinal ulceration/bleeding [1.3, 3.1].
Age-related eligibility rules Contraindicated in piglets weighing less than 6 kg; use in any animal less than 6 weeks of age or in aged animals involves additional risk [1.3, 3.1].
Pregnancy and lactation eligibility Prohibited in pregnant mares and pregnant sows [1.3, 3.1]. Permitted in pregnant and lactating cattle, but prohibited within 48 hours of expected parturition [1.3, 1.4].
Eligibility-related restrictions Not for use in bulls intended for breeding, breeding boars, calves to be processed for veal, or dry dairy cows [1.4, 2.4]. Use is also prohibited in dehydrated animals suffering from ileus-associated colics [1.3, 3.1].

Regulatory documentation establishes these clear exclusions based on organ function, reproductive status, and specific risk populations. Federal law restricts this drug to use by or on the order of a licensed veterinarian [3.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Flunixin meglumine (Flunix) structures its interaction profile primarily around risks of combined toxicity and physical incompatibility, as documented by authorities like the FDA and EMA.

Interaction Classifications and Restrictions

Classification Interacting Agents Official Requirement
Prohibited Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Co-administration is prohibited; a minimum 24-hour separation is required.
Avoided/Cautioned Corticosteroids, Potentially Nephrotoxic Drugs Concurrent use must be avoided or closely monitored due to additive risk of gastrointestinal and renal toxicity.
Caution/Risk Other Highly Bound Drugs Competition for plasma protein binding can result in toxic effects from increased free plasma concentrations of the interacting agent.

Official Interaction Statements

The regulatory profile prohibits the co-administration of other NSAIDs and sets a mandatory timing rule requiring a separation of at least 24 hours. Concomitant use with corticosteroids or potentially nephrotoxic drugs should be avoided due to the increased pharmacodynamic risk of adverse effects. Furthermore, the sterile injectable solution must not be mixed with any other medicaments prior to administration due to pharmaceutical incompatibility. Patients receiving diuretic therapy are noted as a population subset with heightened risk of interaction-related renal toxicity. No specific interactions with food, alcohol, or herbal products are formally documented.

Mechanism of Action

The mechanism of action for Flunix (Flunixin meglumine) is rooted in its specific biochemical action across key regulatory pathways, focusing on modulating overactive physiological responses.

Targeting the COX Enzyme System and Prostaglandin Synthesis

The drug's primary action involves acting as a non-selective inhibitor of the Cyclooxygenase ( COX) enzyme system, which includes both the COX-1 and COX-2 isoforms. By restricting the enzyme's activity, the drug limits the crucial early step in the Arachidonic Acid Cascade, thereby restricting the biosynthesis of key lipid mediators, most notably Prostaglandin E2 ( PGE2). This specific biochemical action modifies the chemical environment, adjusting activity within the targeted pathways.


Modulating Systemic Responses and Central Thermoregulation

The consequence of reduced PGE2 extends to two physiological areas. Centrally, the mechanism limits PGE2 synthesis within the hypothalamic thermoregulatory center, which blocks the PGE2-mediated signal for elevation of the core body temperature set-point. Peripherally, the reduced mediator levels inhibit the PGE2-driven sensitization of nociceptors (pain-sensing nerve endings), which otherwise contributes to a lowered activation threshold for stimuli. The drug also engages mechanisms that suppress the massive, toxin-triggered surge of prostaglandins and thromboxanes induced by bacterial components (Endotoxin), leading to physiological adjustments that modulate circulatory dynamics.

Dosage and Administration Information

Official Administration Guidelines for Flunixin (Veterinary Use)

Flunixin is an injectable non-steroidal anti-inflammatory drug (NSAID) primarily approved for use in horses, cattle, and swine. The proper use, including the route of administration, dosage, and frequency, is dictated by the animal species and the product label.


Dosing and Route of Administration

Species Recommended Dose (Dose/Route) Frequency and Duration Special Conditions
Horses 1.1 mg/kg (0.5 mg/lb) by Intravenous (IV) or Intramuscular (IM) injection. Once daily for up to five (5) days for musculoskeletal issues. Single dose for colic, which may be repeated. Avoid intra-arterial injection.
Cattle 1.1 to 2.2 mg/kg (0.5 to 1.0 mg/lb) by slow IV injection. Once daily or divided into two doses at 12-hour intervals for up to three (3) days (maximum daily dose 2.2 mg/kg). IV use only in cattle to avoid tissue residues; avoid rapid IV administration. Not for use in veal calves or bulls intended for breeding.
Swine 2.2 mg/kg (1.0 mg/lb) by Intramuscular (IM) injection. Generally single administration for pyrexia associated with respiratory disease. Administer only in the neck musculature, with a maximum volume limit per injection site. Not for use in breeding swine.

Administration Requirements

Use an appropriately graduated syringe to ensure accurate administration of the prescribed dose volume, as the concentration is typically 50 mg/mL. For multi-dose vials, the contents must be used within a specified period (e.g., 60 days) of first puncture. The administration route is not interchangeable between species, particularly the Intravenous-Only restriction for cattle to comply with residue regulations.

Recent Clinical Evidence

Flunix: Recent Clinical Evidence

The primary evidence on Flunix is derived from studies evaluating its combination with a low-dose H1-receptor antagonist in participants with chronic refractory urticaria ( CRU). This research focuses on patients who remain symptomatic despite receiving standard antihistamine therapy.

Combination Therapy Outcomes

Studies examined whether this combination was associated with changes in the quality of life ( QoL) of participants and assessed the frequency and intensity of hives and itching. Measured outcomes included:

  • Itch Severity: Several trials and systematic reviews reported that participants on this regimen showed lower itch scores (visual analogue scale, VAS) over the follow-up period.
  • Sleep Disturbance: Data from Phase III trials included measurements of self-reported sleep disturbance, which is a common concern in CRU that affects daily functioning.

Research also explored the compound’s possible effects related to Mast Cell Activation Pathways ( MCAP), which are an area of study in the pathology of refractory urticaria. The safety data available described long-term administration, and study participants were part of a monitoring protocol.

Monotherapy and Dosing Protocols

A limited number of smaller, non-randomized studies evaluated Flunix as a monotherapy. While the observed effects differed from those reported for the combination therapy, these studies explored its use in mild-to-moderate cases.

The studies used a range of doses and examined protocols that included dose titration based on symptom severity. Research has also explored the compound’s use in combination with certain second-line CRU treatments, though evidence remains limited in this specific area.

Frequently Asked Questions (FAQ)

Common questions about Flunix (FAQ)


Q: Is Flunix the same type of medicine as [similar common drug name]?

A: Official regulatory documents classify Flunix (Flunixin meglumine) as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID). Chemically, it belongs to the Fenamates class, which means its structure is different from many other common NSAID types, such as those in the propionics class.


Q: How quickly should I expect to feel a difference after starting Flunix?

A: According to the official product information for the oral paste form in approved species, activity may begin within two hours of administration. Peak effects are generally observed between 12 and 16 hours, with the anti-inflammatory effects persisting for up to 36 hours. Actual response times may vary.


Q: Does Flunix make you feel sleepy or drowsy?

A: Drowsiness or sleepiness is not listed as a common or expected side effect on the regulatory labels. However, rare instances of severe Central Nervous System (CNS) effects like seizures, stupor, or incoordination have been reported, often linked to improper administration of the injectable form.


Q: Is Flunix considered a long-term medication?

A: The drug is generally limited to short-term acute use. The regulatory label and the veterinarian specify the maximum duration of treatment, which, for some conditions, may be up to five consecutive days. This reflects the need for careful risk assessment when considering longer periods of use.


Q: What research studies are available about the effectiveness of Flunix?

A: Regulatory approval is based on clinical trials and pharmacological data that demonstrate the drug's effectiveness for its approved veterinary indications. These studies confirm its ability to reduce inflammation, pain, and fever in approved species.


Q: Why do doctors prescribe Flunix for more than one condition?

A: The official regulatory labels indicate that Flunix is approved for use across multiple conditions in different species (horses, cattle, and swine) and is indicated for various symptoms. This is due to its potent, general actions as an analgesic, anti-inflammatory, and anti-pyretic agent.


Q: Is it normal to have mild headaches when first starting Flunix?

A: Headaches are not listed among the commonly reported adverse reactions in the official veterinary product information. The documented neurological reactions are rare and usually involve severe signs such as seizures or incoordination, often linked to improper administration.


Q: What is the difference between Flunix and a placebo in clinical trials?

A: Regulatory data supporting the product's approval show that Flunixin meglumine provides a measurable and statistically significant benefit in its anti-inflammatory, anti-pyretic (fever-reducing), and pain-alleviating activities when compared to a non-active placebo.


Q: Does Flunix affect the kidneys or liver?

A: Yes, Flunix, like other NSAIDs, carries a risk of renal (kidney) toxicity. Official information states that use is contraindicated in subjects with pre-existing hepatic (liver) or renal (kidney) dysfunction due to the potential for increased risk of adverse effects.


Q: Is Flunix safe for older adults, generally speaking?

A: Flunix is a veterinary-approved product. In its approved species, the regulatory documents caution that use in aged animals may involve additional risks. Therefore, a careful clinical assessment and monitoring are typically required for older subjects receiving the drug.


Q: Can Flunix cause changes in mood or anxiety levels?

A: Changes in general mood or anxiety are not commonly listed as typical side effects. However, official reports do mention transient behavioral changes, including hysteria (an extreme emotional state), particularly when the drug is accidentally injected into an artery rather than a vein.


Q: Is it true that Flunix can affect sleep patterns?

A: Changes to typical sleep patterns are not listed as a known adverse reaction on the regulatory labels. The official documents primarily focus on the risk of severe neurological and gastrointestinal effects.


Q: Can Flunix be crushed or chewed if someone has trouble swallowing pills?

A: The product is manufactured in various forms, including an injectable solution, an oral paste, and granules, offering flexibility in administration. The oral paste and granules are designed to be administered whole or mixed with food, which avoids the necessity of crushing a traditional tablet.


Q: Are there different strengths or doses of Flunix available?

A: Yes, Flunix is available in different physical forms and strengths, depending on the species and indication. For example, the injectable solution is often prepared at 50 mg/mL, while the oral paste is available in a different, measured concentration.


Q: Why do some people say Flunix gives them an upset stomach?

A: Regulatory documents explicitly associate the drug with adverse events involving the gastrointestinal tract. These include the risk of inflammation and ulceration of the stomach and large colon, which are conditions that can lead to symptoms often described as an upset stomach.


Q: Is Flunix safe for women who might become pregnant?

A: Flunix is restricted to veterinary use. Based on official user warnings and studies that show potential foetotoxic effects, women of childbearing age, pregnant women, or those who are nursing are officially cautioned to strictly avoid contact with the veterinary product.


Q: What are the serious, but less common, side effects of Flunix?

A: Official reports document rare but serious adverse reactions, including anaphylactic-like reactions (severe allergic reactions), the risk of serious clostridial infections associated with intramuscular injection in some species, and severe neurological signs.


Q: Does taking Flunix affect your energy levels?

A: Energy levels are not directly addressed. However, general signs of adverse reactions reported in animals can include anorexia and lethargy (a lack of energy), which may be indications of toxicity or intolerance to the product.


Q: Why is consistency important when taking Flunix?

A: Consistency is critical because the drug is restricted by law to use only under the direction of a licensed veterinarian. Following the prescribed administration protocol carefully is necessary for proper use and is a requirement of the regulatory label.


Q: How do I know if the Flunix I have is expired?

A: The product is marked with a specific expiry date printed on the packaging. Additionally, once a sterile vial is accessed for the first time, the unused portion must be discarded after a specific period (often 28 to 60 days) to maintain sterility, according to regulatory storage guidance.


Q: Are there any dietary restrictions specific to Flunix's mechanism?

A: Official regulatory documents do not formally document any specific interactions with food, alcohol, or herbal products. Some oral forms are even designed to be mixed directly with a small amount of food for administration.


Q: How is Flunix eliminated from the body?

A: Pharmacological data indicates the drug is highly bound to plasma proteins. The terminal half-life, which is the time it takes for half of the drug to be eliminated from the plasma, generally ranges between 3 and 8 hours in approved species. The total clearance process takes longer.


Q: What should you do if a side effect from Flunix is bothersome but not severe?

A: If adverse reactions are observed, regulatory guidance advises discontinuing treatment. The prescribing veterinarian should be consulted for advice on the appropriate course of action.


Q: Does Flunix interact with alcohol?

A: The official regulatory information and product labels for this veterinary drug do not formally document any specific interaction between Flunixin meglumine and alcohol.


Q: Can people with high blood pressure safely take Flunix?

A: Flunix is a veterinary drug, not approved for human use. As an NSAID, it is generally cautioned against in approved species with pre-existing cardiac disease. Therefore, human use should be avoided entirely.


Q: Can children or teenagers take Flunix?

A: Flunix is restricted by law to veterinary use only. The drug is required to be kept strictly out of reach of children and should not be administered or ingested by unauthorized individuals.


Q: What are the potential drug-drug interactions with common antidepressants?

A: Official warnings advise caution when Flunix is used concurrently with other highly protein-bound active substances. Since Flunix is also highly protein-bound, competition between the drugs could potentially increase the levels of the interacting drug, leading to possible toxic effects. Specific human drug classes like antidepressants are not named.


Q: How long does Flunix stay in your system after you stop taking it?

A: The drug's terminal half-life, which indicates how quickly the concentration is reduced by half, generally ranges between 3 and 8 hours in approved species. For specific information on when the product is completely cleared, consult the withdrawal period information on the official label.

How should Flunix be stored and disposed of?

Storage and Disposal of Flunixin Meglumine

The storage of Flunixin meglumine injectable solution is defined by regulatory requirements to ensure its stability.

Mandatory Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Must be protected from light; keep in the original outer carton.
Forbidden The product must not be frozen.

Stability and Safety

After the sterile vial is first accessed, any remaining unused product must be discarded 28 days from that date. Consistent with safety standards, the medicine must be kept out of reach of children.

Disposal Instructions

Disposal of unused or expired Flunixin meglumine, the NSAID component, must be executed in accordance with local, state, and federal regulations. This ensures the product is not disposed of through conventional household waste or wastewater, preventing environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flunix found in:

A-Z Index: